MyFinsight
Home
Blog
About
2031 and thereafter
$31,936K
2030
$6,449K
2028
$6,449K
2027
$6,449K
2027-Cost Of Sales Product
$6,382K
2026 (remainder of
year)
$3,224K
2027-Selling General And
Administrative
$67K
Cash and cash
equivalents
$5,098,041K
Accounts receivable, net
$1,056,177K
Inventories, net
$732,603K
Prepaid expenses and
other current assets
$328,984K
Property, plant and
equipment, net
$1,643,286K
Operating lease
right-of-use assets
$145,987K
Other non-current
assets
$109,581K
Intangible assets, net
$60,956K
Total current assets
$7,215,805K
Total non-current
assets
$1,959,810K
Total assets
$9,175,615K
Total liabilities and
shareholders equity
$9,175,615K
Total shareholders
equity
$5,173,998K
Total liabilities
$4,001,617K
Accumulated deficit
-$7,855,539K
Accumulated other
comprehensive loss
-$25,370K
Additional paid-in capital
$13,054,760K
Total current
liabilities
$2,119,187K
Total non-current
liabilities
$1,882,430K
Ordinary shares, 0.0001
par value per share...
$147K
Accrued expenses and
other payables
$1,264,264K
Accounts payable
$470,299K
Short-term debt
$190,896K
Sale of future
royalty liability,...
$89,278K
Tax payable
$76,315K
Operating lease
liabilities, current portion
$21,953K
Research and development
cost share...
$6,182K
Long-term debt
$882,163K
Sale of future
royalty liability,...
$817,035K
Other long-term
liabilities
$77,644K
Deferred tax liabilities
$57,388K
Operating lease
liabilities, non-current...
$48,200K
Back
Back
Balance Sheet
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)
source: myfinsight.com